Clinical significance of HuR expression, an mRNA-binding protein in non-small cell lung cancer (NSCLC)

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10098-10098
Author(s):  
F. Tanaka ◽  
E. Ogawa ◽  
H. Wada ◽  
M. Shanker ◽  
A. E. Garcia-Soto ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Tumor Progression ◽  
Clinical Significance ◽  
Survival Rates ◽  
Protein Translation ◽  
Independent Prognostic Factor ◽  
Significant Prognostic Factor ◽  
Cell Cycle Regulators ◽  
Mrna Stabilization ◽  
Cox 2

10098 Background: HuR is a nucleo-cytoplasmic shuttling protein that specifically binds to mRNA that has AU rich (ARE) sites at the 3’end and transports the RNA to the cytoplasm for protein translation. In addition to mRNA transportation, HuR plays a role in mRNA stabilization and protein translation. Preclinical studies have shown mRNA’s of several growth factors, cell-cycle regulators, and transcription-regulating proteins have ARE’s at the 3’end and bound by HuR. However, there has been reported no clinical data on HuR expression in NSCLC. Thus, in the present study, we assessed clinical significance of HuR expression in NSCLC. Patients and Methods: A total of 236 patients with completely resected p-stage I-IIIA, NSCLC, were reviewed, and HuR expression was evaluated immunohistochemically. Results (Table): HuR expression was seen in the nucleus and cytoplasm of tumor cells. Cytoplasmic HuR expression was positively correlated with tumor progression (p-stage, P<0.01), especially nodal metastasis, microvessel density (MVD), and COX-2 expression. Enhanced nuclear HuR expression was also correlated with tumor progression and COX-2 expression, but not with MVD. Positive cytoplasmic HuR expression was a significant factor to predict a poor prognosis in all patients (5-year survival rates: 85% for HuR-negative and 43% for HuR-positive patients; P<0.01) and in any p-stage/histology subset patients. Nuclear HuR expression status was also a significant prognostic factor in all patients, but not in all subsets. A multivariate analysis confirmed that cytoplasmic HuR status was an independent prognostic factor (hazard ratio [95% CI], 4.261 [2.109–8.609]; P<0.001). Conclusions: Cytoplasmic HuR expression was correlated with tumor progression, and was a significant and independent prognostic factor in correlation with enhanced COX-2 expression and increased tumor angiogenesis. [Table: see text] No significant financial relationships to disclose.

p27kip1 Protein Expression Correlates With Survival in Myxoid and Round-Cell Liposarcoma

2000 ◽  
Vol 18 (15) ◽  
pp. 2888-2893 ◽  
Author(s):  
Andre M. Oliveira ◽  
Antonio G. Nascimento ◽  
Scott H. Okuno ◽  
Ricardo V. Lloyd
Keyword(s):  
Overall Survival ◽  
Cell Differentiation ◽  
Prognostic Factor ◽  
Kinase Inhibitor ◽  
Survival Rates ◽  
Independent Prognostic Factor ◽  
Rank Test ◽  
Round Cell ◽  
Ki 67 ◽  
Low Expression

PURPOSE: The p27kip1 protein (p27) is a cyclin-dependent kinase inhibitor that has been shown to be an independent prognostic factor in a variety of human neoplasms. Low expression of p27 tends to occur in more aggressive neoplasms. The role of p27 as an independent prognostic factor in the spectrum of myxoid and round-cell liposarcomas has not been examined. MATERIALS AND METHODS: Forty-seven cases of myxoid and round-cell liposarcomas were examined. Clinicopathologic features and immunohistochemical expression of p27 and Ki-67 antigen were studied in all cases. Survival analysis was performed using the log-rank test and the Cox multivariate regression model. RESULTS: The male:female ratio was 1.4:1, and the mean age at diagnosis was 45 years. The tumors were located in the lower extremities (94%) and retroperitoneum (6%). The median tumor size was 13.5 cm. The median follow-up was 6.3 years, and the overall 5- and 10-year survival rates were 76% and 67%, respectively. Low expression of p27 was identified in 34 cases (72%) and correlated with decreased metastasis-free (P = .026) and overall survival (P = .008). In a multivariate analysis, only round-cell differentiation and low expression of p27 independently predicted decreased metastasis-free and overall survival. CONCLUSION: p27 expression predicts the clinical behavior of myxoid and round-cell liposarcomas, even in neoplasms with few or no round-cell differentiation.

PROSTATIC APEX INVOLVEMENT IN THE SPECIMEN OF RADICAL PROSTATECTOMY IS AN INDEPENDENT PROGNOSTIC FACTOR OF TUMOR PROGRESSION

2008 ◽  
Vol 179 (4S) ◽  
pp. 495-495
Author(s):  
Lorenzo Masieri ◽  
Sergio Serni ◽  
Michele Lanciotti ◽  
Andrea Minervini ◽  
Alberto Lapini ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Radical Prostatectomy ◽  
Tumor Progression ◽  
Independent Prognostic Factor

COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer

Tumor Biology ◽  
2009 ◽  
Vol 31 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Johanna Mrena ◽  
Jan-Patrik Wiksten ◽  
Arto Kokkola ◽  
Stig Nordling ◽  
Ari Ristimäki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Independent Prognostic Factor ◽  
Proliferation And Apoptosis ◽  
Apoptosis Markers ◽  
Cox 2

scholarly journals Clinical significance and therapeutic implication of CD200 in pancreatic cancer

2019 ◽  
Author(s):  
Shoichi Kinoshita ◽  
Masayuki Sho ◽  
Takahiro Akahori ◽  
Satoshi Nishiwada ◽  
Minako Nagai ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Stem Cell ◽  
Prognostic Factor ◽  
Cancer Stem Cell ◽  
Clinical Significance ◽  
Systemic Therapy ◽  
Stem Cell Marker ◽  
Human Pancreatic Cancer ◽  
Significant Prognostic Factor ◽  
Stem Cell Markers

Abstract Background CD200, a negative T cell regulator as well as a cancer stem cell marker, is a significant prognostic factor and potential therapeutic target in specific cancers. However, the clinical significance of CD200 is unknown in pancreatic ductal adenocarcinoma (PDAC). Methods CD200 was evaluated in 220 resected PDAC patients. Surgery was performed with or without neoadjuvant chemotherapy (NACRT), and adjuvant therapy was administered with systemic therapy or systemic therapy added with hepatic arterial infusion (HAI) therapy. We investigated the clinicopathological outcomes associated with CD200, in relation to the administered multimodal treatment. We further evaluated the impact of the immunological and cancer stem cell properties associated with CD200. Results NACRT patients had a lower average age, lower lymph node metastasis, higher negative surgical margins, and higher HAI administration rate, compared to upfront surgery (US) patients. NACRT was associated with better OS, and higher CD200 expression (66.4% vs. 32.2%, P<0.001) compared to US. CD200 was an independent poor prognostic factor in NACRT (hazard ratio 2.51; 95% confidence interval 1.35-4.66; P = 0.004), but not in US patients. In NACRT patients, the hepatic recurrence rate was relatively high in CD200+ cases despite HAI therapy. CD200 was associated with significantly lower CD4+, CD8+, and CD45RO+ tumor-infiltrating lymphocyte levels. Furthermore, the correlation of CD200 with pancreatic cancer stem cell markers CD44/CD24/ESA was stronger in irradiated human pancreatic cancer cells. Conclusions Our data highlight novel roles for CD200 in immune evasion as well as therapy resistance in pancreatic cancer.

p16INK4a immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia

Blood ◽  
2002 ◽  
Vol 99 (7) ◽  
pp. 2620-2623 ◽  
Author(s):  
Jean Hughes Dalle ◽  
Martine Fournier ◽  
Brigitte Nelken ◽  
Françoise Mazingue ◽  
Jean-Luc Laı̈ ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Prognostic Factor ◽  
Lymphoblastic Leukemia ◽  
Independent Prognostic Factor ◽  
Childhood Acute Lymphoblastic Leukemia ◽  
Significant Prognostic Factor ◽  
Event Free Survival ◽  
Childhood All ◽  
Free Survival ◽  
First Relapse

We investigated the prognostic value of p16INK4aimmunocytochemistry (ICC) analysis in 126 cases of newly diagnosed childhood acute lymphoblastic leukemia (ALL). The incidence of negative p16INK4a ICC was 38.1% and was more frequent in T-lineage ALL. Overall survival (OS) and event-free survival (EFS) were significantly higher in patients with positive p16INK4a ICC than in patients with negative ICC (6 years OS, 90% versus 63%,P = .0014; 6 years EFS, 77.8% versus 55%,P = .0033). The p16INK4a ICC remained a significant prognostic factor within the subgroup of B-precursor ALL. Multivariate analysis showed that negative p16INK4a ICC was an independent prognostic factor for OS (relative risk [RR], 3.38;P = .02) and EFS (RR, 2.49; P = .018). Sequential study showed that p16INK4a expression remained stable during first relapse in most patients. These findings indicate that p16INK4a ICC is an independent factor of outcome in childhood ALL.

scholarly journals The AST/ALT (De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Cancer

Diagnostics ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 973
Author(s):  
Olivia Knittelfelder ◽  
Daniela Delago ◽  
Gabi Jakse ◽  
Sabine Reinisch ◽  
Richard Partl ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Prognostic Factor ◽  
Cox Regression ◽  
Cell Cancer ◽  
Survival Rates ◽  
Prognostic Significance ◽  
Independent Prognostic Factor ◽  
Operating Characteristics ◽  
Roc Curve Analysis ◽  
Cancer Specific Survival

Aminotransaminases, including aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT), are strongly involved in cancer cell metabolism and have been associated with prognosis in different types of cancer. The purpose of the present study was to evaluate the prognostic significance of the pre-treatment AST/ALT ratio in a large European cohort of patients with oral and oropharyngeal squamous cell cancer (OOSCC). Data from 515 patients treated for OOSCC at a tertiary academic center from 2000–2017 were retrospectively analyzed. Levels of AST and ALT were measured prior to the start of treatment. Uni- and multivariate Cox regression analyses were applied to evaluate the prognostic value of the AST/ALT ratio for cancer-specific survival (CSS) and overall survival (OS), survival rates were calculated. Univariate analyses showed a significant association of the AST/ALT ratio with CSS (hazard ratio (HR) 1.71, 95% confidence interval (CI) 1.38–2.12; p < 0.001) and OS (HR 1.69, 95% CI 1.41–2.02; p < 0.001). In multivariate analysis, the AST/ALT ratio remained an independent prognostic factor for CSS and OS (HR 1.45, 95% CI 1.12–1.88, p = 0.005 and HR 1.42, 95% CI 1.14–1.77, p = 0.002). Applying receiver operating characteristics (ROC) curve analysis, the optimal cut-off level for the AST/ALT ratio was 1.44, respectively. In multivariate analysis, an AST/ALT ratio > 1.44 was an independent prognostic factor for poor CSS and OS (HR 1.64, 95% CI 1.10–2.43, p = 0.014 and HR 1.55, 95% CI 1.12–2.15; p = 0.008). We conclude that the AST/ALT ratio is a prognostic marker for survival in OOSCC patients and could contribute to a better risk stratification and improved oncological therapy decisions.

Clinical Significance of Circulating Tumor Cells, Including Cancer Stem-Like Cells, in Peripheral Blood for Recurrence and Prognosis in Patients With Dukes' Stage B and C Colorectal Cancer

2011 ◽  
Vol 29 (12) ◽  
pp. 1547-1555 ◽  
Author(s):  
Hisae Iinuma ◽  
Toshiaki Watanabe ◽  
Koshi Mimori ◽  
Miki Adachi ◽  
Naoko Hayashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Significance ◽  
Peripheral Blood ◽  
Disease Free Survival ◽  
Significant Prognostic Factor ◽  
Curative Surgery ◽  
Validation Set

Purpose Using multiple genetic markers, including cancer stem-like cells, we evaluated the clinical significance of circulating tumor cells (CTCs) as a prognostic factor for overall survival (OS) and disease-free survival (DFS) in the peripheral blood (PB) of patients with colorectal cancer (CRC) who had undergone curative surgery. Patients and Methods In a multi-institutional study, 735 patients with CRC were assigned to a retrospective training set (n = 420) or prospective validation set (n = 315). CTCs that expressed carcinoembryonic antigen (CEA), cytokeratin (CK) 19, CK20, and/or CD133 (CEA/CK/CD133) mRNA in PB were detected using real-time reverse transcription polymerase chain reaction assay. Results In the training sets, OS and DFS of patients who were positive for CEA/CK/CD133 were significantly worse than those of patients who were negative for these markers (P < .001). At each staging analysis, OS and DFS of patients with Dukes' stage B or C cancer who were positive for CEA/CK/CD133 were significantly worse than those of patients who were negative for these markers (P < .003 and P < .001 in Dukes' stage B; P < .001 in Dukes' stage C). In contrast, in patients with Dukes' stage A, no significant differences were seen between patients who were positive for these markers and those who were negative. Cox multivariate analysis demonstrated that CEA/CK/CD133 was a significant prognostic factor for OS (hazard ratio [HR], 3.84; 95% CI, 2.41 to 6.22; P < .001) and DFS (HR, 3.02; 95% CI, 1.83 to 5.00; P < .001). In particular, in patients with Dukes' stage B and C cancer, CEA/CK/CD133 demonstrated significant prognostic value. In validation sets, similar results were confirmed in patients with Dukes' stage B and C cancer. Conclusion In patients with Dukes' stage B and C CRC who require adjuvant chemotherapy, detection of CEA/CK/CD133 mRNA in PB is a useful tool for determining which patients are at high risk for recurrence and poor prognosis.

T1G3 bladder carcinoma: Can we still judge them as superficial tumours?

1995 ◽  
Vol 62 (1_suppl) ◽  
pp. 144-149
Author(s):  
S. Pagano ◽  
F. Franzoso
Keyword(s):  
High Risk ◽  
Prognostic Factor ◽  
Conservative Treatment ◽  
Survival Rates ◽  
Cytotoxic Chemotherapy ◽  
Significant Prognostic Factor ◽  
Treatment Results ◽  
Risk Of Progression ◽  
Bladder Carcinomas

— T1G3 bladder carcinomas are classified as superficial tumours and treatment results are included in low stage tumour groups. A review of survival rates shows that there is a high risk of progression, about 50–78%. Among other things this is due to some commonly-accepted factors. The grade is by now considered the most significant prognostic factor. It is easy in this stage for clinical understaging to occur and cases of N + are to be found in all early cystectomies. Another important factor is the differing interpretations by pathologists of the pT category and grade. With conservative treatment there is a progression of 50% after radiotherapy, 40% after endoscopic surgery and 40% after cytotoxic chemotherapy. Better results with BCG immunotherapy are reported with 10–19% progression; however, there is no significant follow-up yet in these cases and they often refer to all superficial tumours including T1G3 which taken singly have clearly worse percentages of recurrence and progression. Best survival rates are achieved with early cystectomy (76–95% at 5 years). These data advise considering T1G3 carcinomas clinically like invasive tumours and early cystectomy as the best therapy, while the risks of delaying cystectomy should be fully assessed.

Sign in / Sign up

Export Citation Format

Share Document